|
1
|
Hovland S, Muller S, Skomedal H, Mints M,
Bergström J, Wallin KL, Karlsen F, Johansson B and Andersson S:
E6/E7 mRNA expression analysis: A test for the objective assessment
of cervical adenocarcinoma in clinical prognostic procedure. Int J
Oncol. 36:1533–1539. 2010.PubMed/NCBI
|
|
2
|
Wolfson IN: Letter: Blind defibrillation.
Am J Cardiol. 36:4121975. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sankaranarayanan R and Ferlay J: Worldwide
burden of gynaecological cancer: The size of the problem. Best
Pract Res Clin Obstet Gynaecol. 20:207–225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arbyn M, Castellsague X, de Sanjose S,
Bruni L, Saraiya M, Bray F and Ferlay J: Worldwide burden of
cervical cancer in 2008. Anna Oncol. 22:2675–2686. 2011. View Article : Google Scholar
|
|
5
|
Andrae B, Andersson TM, Lambert PC,
Kemetli L, Silfverdal L, Strander B, Ryd W, Dillner J, Törnberg S
and Sparén P: Screening and cervical cancer cure: Population based
cohort study. BMJ. 344:e9002012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: Mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
7
|
Huang R and Rofstad EK: Cancer stem cells
(CSCs), cervical CSCs and targeted therapies. Oncotarget.
8:35351–35367. 2017.PubMed/NCBI
|
|
8
|
Iden M, Fye S, Li K, Chowdhury T,
Ramchandran R and Rader JS: The lncRNA PVT1 contributes to the
cervical cancer phenotype and associates with poor patient
prognosis. PLoS One. 11:e01562742016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Canuto RA, Muzio G, Salvo RA, Maggiora M,
Trombetta A, Chantepie J, Fournet G, Reichert U and Quash G: The
effect of a novel irreversible inhibitor of aldehyde dehydrogenases
1 and 3 on tumour cell growth and death. Chem Biol Interact.
130-132:209–218. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang M, Shoeb M, Goswamy J, Liu P, Xiao
TL, Hogan D, Campbell GA and Ansari NH: Overexpression of aldehyde
dehydrogenase 1A1 reduces oxidation-induced toxicity in SH-SY5Y
neuroblastoma cells. J Neurosci Res. 88:686–694. 2010.PubMed/NCBI
|
|
11
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nalwoga H, Arnes JB, Wabinga H and Akslen
LA: Expression of aldehyde dehydrogenase 1 (ALDH1) is associated
with basal-like markers and features of aggressive tumours in
African breast cancer. Br J Cancer. 102:369–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sladek NE, Kollander R, Sreerama L and
Kiang DT: Cellular levels of aldehyde dehydrogenases (ALDH1A1 and
ALDH3A1) as predictors of therapeutic responses to
cyclophosphamide-based chemotherapy of breast cancer: A
retrospective study. Rational individualization of
oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer
Chemother Pharmacol. 49:309–321. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao L, Zhang Z, Lou H, Liang J, Yan X, Li
W, Xu Y and Ou R: Exploration of the molecular mechanisms of
cervical cancer based on mRNA expression profiles and predicted
microRNA interactions. Oncol Lett. 15:8965–8972. 2018.PubMed/NCBI
|
|
15
|
Ding J, Xu Z, Zhang Y, Tan C, Hu W, Wang
M, Xu Y and Tang J: Exosome-mediated miR-222 transferring: An
insight into NF-kappaB-mediated breast cancer metastasis. Exp Cell
Res. 369:129–138. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Di Fazio P, Maass M, Roth S, Meyer C,
Grups J, Rexin P, Bartsch DK and Kirschbaum A: Expression of
hsa-let-7b-5p, hsa-let-7f-5p, and hsa-miR-222-3p and their putative
targets HMGA2 and CDKN1B in typical and atypical carcinoid tumors
of the lung. Tumour Biol. 39:10104283177284172017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Y, Zhao L, Shi B, Ma S, Xu Z, Ge Y, Liu
Y, Zheng D and Shi J: Functions of miR-146a and miR-222 in
tumor-associated macrophages in breast cancer. Sci Rep.
5:186482015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu K, Liang X, Shen K, Sun L, Cui D, Zhao
Y, Tian J, Ni L and Liu J: MiR-222 modulates multidrug resistance
in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell
Res. 318:2168–2177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rao X, Di Leva G, Li M, Fang F, Devlin C,
Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP:
MicroRNA-221/222 confers breast cancer fulvestrant resistance by
regulating multiple signaling pathways. Oncogene. 30:1082–1097.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marth C, Landoni F, Mahner S, McCormack M,
Gonzalez- Martin A and Colombo N; ESMO Guidelines Committee, :
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 29 (Suppl 4):iv2622018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamaguchi M, Dieffenbach CW, Connolly R,
Cruess DF, Baur W and Sharefkin JB: Effect of different laboratory
techniques for guanidinium-phenol-chloroform RNA extraction on
A260/A280 and on accuracy of mRNA quantitation by reverse
transcriptase-PCR. PCR Methods Appl. 1:286–290. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heid CA, Stevens J, Livak KJ and Williams
PM: Real time quantitative PCR. Genome Res. 6:986–994. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hakama M, Coleman MP, Alexe DM and Auvinen
A: Cancer screening: Evidence and practice in Europe 2008. Eur J
Cancer. 44:1404–1413. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nozaki Y, Tamori S, Inada M, Katayama R,
Nakane H, Minamishima O, Onodera Y, Abe M, Shiina S, Tamura K, et
al: Correlation between c-Met and ALDH1 contributes to the survival
and tumor-sphere formation of ALDH1 positive breast cancer stem
cells and predicts poor clinical outcome in breast cancer. Genes
Cancer. 8:628–639. 2017.PubMed/NCBI
|
|
26
|
Choudhary S, Xiao T, Vergara LA,
Srivastava S, Nees D, Piatigorsky J and Ansari NH: Role of aldehyde
dehydrogenase isozymes in the defense of rat lens and human lens
epithelial cells against oxidative stress. Invest Ophthalmol Vis
Sci. 46:259–267. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Quash G, Fournet G, Chantepie J, Gore J,
Ardiet C, Ardail D, Michal Y and Reichert U: Novel competitive
irreversible inhibitors of aldehyde dehydrogenase (ALDH1):
Restoration of chemosensitivity of L1210 cells overexpressing ALDH1
and induction of apoptosis in BAF(3) cells overexpressing bcl(2).
Biochem Pharmacol. 64:1279–1292. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim MJ, Kim AR, Jeong JY, Kim KI, Kim TH,
Lee C, Chung K, Ko YH and An HJ: Correlation of ALDH1 and notch3
expression: Clinical implication in ovarian carcinomas. J Cancer.
8:3331–3342. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng R, Wang J, Wu Q, Wang Z, Ou Y, Ma L,
Wang M, Wang J and Yang Y: Expression of ALDH1 and TGFβ2 in benign
and malignant breast tumors and their prognostic implications. Int
J Clin Exp Pathol. 7:4173–4183. 2014.PubMed/NCBI
|
|
30
|
House CD, Jordan E, Hernandez L, Ozaki M,
James JM, Kim M, Kruhlak MJ, Batchelor E, Elloumi F, Cam MC and
Annunziata CM: NFκB promotes ovarian tumorigenesis via classical
pathways that support proliferative cancer cells and alternative
pathways that support ALDH+ cancer stem-like cells. Cancer Res.
77:6927–6940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang L, Liu Y, Zhou Y, Wang J, Tu L, Sun
Z, Wang X and Luo F: Zoledronic acid inhibits the growth of cancer
stem cell derived from cervical cancer cell by attenuating their
stemness phenotype and inducing apoptosis and cell cycle arrest
through the Erk1/2 and Akt pathways. J Exp Clin Cancer Res.
38:932019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kaehler M, Ruemenapp J, Gonnermann D,
Nagel I, Bruhn O, Haenisch S, Ammerpohl O, Wesch D, Cascorbi I and
Bruckmueller H: MicroRNA-212/ABCG2-axis contributes to development
of imatinib-resistance in leukemic cells. Oncotarget.
8:92018–92031. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu Q, Guo L, Jiang F, Li L, Li Z and Chen
F: Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast
cancer cell lines. J Cell Mol Med. 19:2874–2887. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H
and Zhou X: MicroRNA-222 regulates cell invasion by targeting
matrix metalloproteinase 1 (MMP1) and manganese superoxide
dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines.
Cancer Genomics Proteomics. 6:131–139. 2009.PubMed/NCBI
|
|
35
|
Aherne ST, Smyth P, Freeley M, Smith L,
Spillane C, O'Leary J and Sheils O: Altered expression of mir-222
and mir-25 influences diverse gene expression changes in
transformed normal and anaplastic thyroid cells, and impacts on MEK
and TRAIL protein expression. Int J Mol Med. 38:433–445. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lloyd KA, Moore AR, Parsons BN, O'Hara A,
Boyce M, Dockray GJ, Varro A and Pritchard DM: Gastrin-induced
miR-222 promotes gastric tumor development by suppressing p27kip1.
Oncotarget. 7:45462–45478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Choi B, Yu J, Han TS, Kim YK, Hur K, Kang
BC, Kim WH, Kim DY, Lee HJ, Kim VN and Yang HK: Gastric
carcinogenesis in the miR-222/221 transgenic mouse model. Cancer
Res Treat. 49:150–160. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ying X, Wu Q, Wu X, Zhu Q and Wang X,
Jiang L, Chen X and Wang X: Epithelial ovarian cancer-secreted
exosomal miR-222-3p induces polarization of tumor-associated
macrophages. Oncotarget. 7:43076–43087. 2016. View Article : Google Scholar : PubMed/NCBI
|
